oalib

Publish in OALib Journal

ISSN: 2333-9721

APC: Only $99

Submit

Any time

2018 ( 8 )

2017 ( 6 )

2016 ( 6 )

2015 ( 13 )

Custom range...

Search Results: 1 - 10 of 388 matches for " Junji Tsurutani "
All listed articles are free for downloading (OA Articles)
Page 1 /388
Display every page Item
Practical Use of Gemcitabine and Cisplatin Combination Therapy as First-Line Treatment for Japanese Patients with Advanced Biliary Tract Cancer  [PDF]
Hisato Kawakami, Isamu Okamoto, Wataru Okamoto, Masayuki Takeda, Shinya Ueda, Toshihiro Kudo, Shin-ichi Nishina, Yasuhito Fujisaka, Masaki Miyazaki, Junji Tsurutani, Takayasu Kurata, Kazuhiko Nakagawa
Journal of Cancer Therapy (JCT) , 2013, DOI: 10.4236/jct.2013.46121
Abstract:

Gemcitabine and cisplatin combination therapy (GC) is accepted as a standard treatment for advanced biliary tract cancer (BTC). However, little information is available regarding such treatment in the clinical practice setting in Japan. We retrospectively examined the clinical data of patients with unresectable or recurrent BTC who received GC as first-line treatment. The regimen consisted of cisplatin (25 mg/m2) and gemcitabine (1000 mg/m2) administered intravenously on days 1 and 8 of repeated 3-week cycles. Twenty patients were analyzed. A total of 148 cycles of GC was administered, with a median of 8 and a range of 1 to 18 cycles. Treatment delay and dose reduction were noted in 35 (24%) and 41 (28%) of the 148 cycles, respectively. The major adverse events of grade 3 or 4 included neutropenia (50%), leukopenia (45%), anemia (30%), and thrombocytopenia (15%). Nonhematologic toxicities included nausea (10%), appetite loss (10%), and fatigue (10%). Median progression-free and overall survival times were 6.9 and 12.3 months, respectively. Gallbladder cancer showed a significantly higher response rate than did other types of BTC (chi-squaretest, P = 0.002). GC was thus effective and well tolerated as first-line chemotherapy for Japanese patients with advanced BTC in the clinical practice setting.

Why Are Children Impatient? Evolutionary Selection of Preferences  [PDF]
Junji Kageyama
Theoretical Economics Letters (TEL) , 2013, DOI: 10.4236/tel.2013.35A3003
Abstract:

This study aims to explain why children are impatient. Using a biological framework called the life history theory, the study investigates the evolutionary root of time preference, paying particular attention to childhood. The results show that the biologically endowed rate of time preference is equal to the mortality rate not only in adulthood but also in childhood, reflecting the change in the biological value of survival. Mortality is the baseline for time preference through the entire course of life. These results are consistent with the findings in previous empirical and experimental studies that the discount rate is U-shaped in age, and account for why young children, in particular, are impatient. In addition, the difference in time preference between adults and children provides a biological explanation for the parent-offspring conflict, in which the higher discount rate among children causes parents and their children to disagree over intertemporal allocation of resources in collective decision-making particularly within the household.

Loss of Cytoplasmic CDK1 Predicts Poor Survival in Human Lung Cancer and Confers Chemotherapeutic Resistance
Chunyu Zhang, Abdel G. Elkahloun, Matthew Robertson, Joell J. Gills, Junji Tsurutani, Joanna H. Shih, Junya Fukuoka, M. Christine Hollander, Curtis C. Harris, William D. Travis, Jin Jen, Phillip A. Dennis
PLOS ONE , 2011, DOI: 10.1371/journal.pone.0023849
Abstract: The dismal lethality of lung cancer is due to late stage at diagnosis and inherent therapeutic resistance. The incorporation of targeted therapies has modestly improved clinical outcomes, but the identification of new targets could further improve clinical outcomes by guiding stratification of poor-risk early stage patients and individualizing therapeutic choices. We hypothesized that a sequential, combined microarray approach would be valuable to identify and validate new targets in lung cancer. We profiled gene expression signatures during lung epithelial cell immortalization and transformation, and showed that genes involved in mitosis were progressively enhanced in carcinogenesis. 28 genes were validated by immunoblotting and 4 genes were further evaluated in non-small cell lung cancer tissue microarrays. Although CDK1 was highly expressed in tumor tissues, its loss from the cytoplasm unexpectedly predicted poor survival and conferred resistance to chemotherapy in multiple cell lines, especially microtubule-directed agents. An analysis of expression of CDK1 and CDK1-associated genes in the NCI60 cell line database confirmed the broad association of these genes with chemotherapeutic responsiveness. These results have implications for personalizing lung cancer therapy and highlight the potential of combined approaches for biomarker discovery.
Risk Factors for Cisplatin-Induced Nephrotoxicity and Potential of Magnesium Supplementation for Renal Protection
Yasuhiro Kidera, Hisato Kawakami, Tsutomu Sakiyama, Kunio Okamoto, Kaoru Tanaka, Masayuki Takeda, Hiroyasu Kaneda, Shin-ichi Nishina, Junji Tsurutani, Kimiko Fujiwara, Morihiro Nomura, Yuzuru Yamazoe, Yasutaka Chiba, Shozo Nishida, Takao Tamura, Kazuhiko Nakagawa
PLOS ONE , 2014, DOI: 10.1371/journal.pone.0101902
Abstract: Background Nephrotoxicity remains a problem for patients who receive cisplatin chemotherapy. We retrospectively evaluated potential risk factors for cisplatin-induced nephrotoxicity as well as the potential impact of intravenous magnesium supplementation on such toxicity. Patients and Methods We reviewed clinical data for 401 patients who underwent chemotherapy including a high dose (≥60 mg/m2) of cisplatin in the first-line setting. Nephrotoxicity was defined as an increase in the serum creatinine concentration of at least grade 2 during the first course of cisplatin chemotherapy, as assessed on the basis of National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0. The severity of nephrotoxicity was evaluated on the basis of the mean change in the serum creatinine level. Magnesium was administered intravenously to 67 patients (17%). Results Cisplatin-induced nephrotoxicity was observed in 127 patients (32%). Multivariable analysis revealed that an Eastern Cooperative Oncology Group performance status of 2 (risk ratio, 1.876; P = 0.004) and the regular use of nonsteroidal anti-inflammatory drugs (NSAIDs) (risk ratio, 1.357; P = 0.047) were significantly associated with an increased risk for cisplatin nephrotoxicity, whereas intravenous magnesium supplementation was associated with a significantly reduced risk for such toxicity (risk ratio, 0.175; P = 0.0004). The development of hypomagnesemia during cisplatin treatment was significantly associated with a greater increase in serum creatinine level (P = 0.0025). Magnesium supplementation therapy was also associated with a significantly reduced severity of renal toxicity (P = 0.012). Conclusions A relatively poor performance status and the regular use of NSAIDs were significantly associated with cisplatin-induced nephrotoxicity, although the latter association was marginal. Our findings also suggest that the ability of magnesium supplementation to protect against the renal toxicity of cisplatin warrants further investigation in a prospective trial.
Measurement of Surface SH-Wave Velocities Generated on the Surface of Japanese Cypress Column  [PDF]
Masumi Hasegawa, Junji Matsumura
Open Journal of Acoustics (OJA) , 2014, DOI: 10.4236/oja.2014.44018
Abstract: Polyetherimide resin wedge transducers were used to generate a shear wave that was obliquely incident relative to the surface of a Japanese cypress column for measuring the surface SH-wave velocity. As the inter-transducer distance increased, the propagation time increased and the am-plitude became smaller. The propagation time and the amplitude were significantly correlated with the inter-transducer distance. The SH-wave velocity ranged from 1270 m/s to 1496 m/s. Surface SH-wave velocity was lower in the central part of the column and higher in the outer part. Velocity was negatively correlated with moisture content at 1% of significance level. These results suggest the accomplishment of the first target for applying the surface SH-wave acoustoelastic technique to nondestructive evaluation of drying stress in wood.
Preface "Nonlinear plasma waves in space and laboratories"
B. Tsurutani,G. Morales
Nonlinear Processes in Geophysics (NPG) , 2011,
Abstract: No available.
New spherically symmetric solutions in Einstein-Yang-Mills-Higgs model
Jia, Junji
High Energy Physics - Phenomenology , 2008,
Abstract: We study classical solutions in the SU(2) Einstein-Yang-Mills-Higgs theory. The spherically symmetric ans\"atze for all fields are given and the equations of motion are derived as a system of ordinary differential equations. The asymptotics and the boundary conditions at space origin for regular solutions and at event horizon for black hole solutions are studied. Using the shooting method, we found numerical solutions to the theory. For regular solutions, we find two new sets of asymptotically flat solutions. Each of these sets contains continua of solutions in the parameter space spanned by the shooting parameters. The solutions bifurcate along these parameter curves and the bifurcation are argued to be due to the internal structure of the model. Both sets of the solutions are asymptotically flat but one is exponentially so and the other is so with oscillations. For black holes, a new set of boundary conditions is studied and it is found that there also exists a continuum of black hole solutions in parameter space and similar bifurcation behavior is also present to these solutions. The SU(2) charges of these solutions are found zero and these solutions are proven to be unstable.
Charged Lepton-Flavor Violation in Beyond-Standard Models
Hisano, Junji
High Energy Physics - Phenomenology , 2008,
Abstract: I discuss charged lepton-flavor violation in physics beyond the standard model and review topics related to it.
Implementation of Market Orientation in Small Sized Company: Case Study on a Japanese Apparel Manufacturer
Junji Inoguchi
International Journal of Emerging Sciences , 2011,
Abstract: This is the case study of an Japanese apparel manufacturers aimed for revealing the process and important factors for the implementations of market orientation in small to medium sized companies. Although there is huge accumulation of studies for Market Orientation, most of them are focused on developing scales and variables of market orientation or analyzing relations between parameters quantitatively. So little effort has been paid for qualitative research with concrete case. Especially, there are few researches on market orientation implementation for small sized firms. The author highlights the important factors for Market Orientation of small sized companies. Those are (a) generation of market intelligence by itself, (b) response to customers’ complex needs by multiple firms, (c) the capability for network coordination based on its market intelligence. In additions, this research indicates the concept of “Market Orientation” can be expanded to multi firms such as network. Prior researches basically supposed generation of market intelligence and the response to it by groups or organizations in a single firm.
Sorafenib for the treatment of unresectable hepatocellular carcinoma
Junji Furuse
Biologics: Targets and Therapy , 2008,
Abstract: Junji FuruseDepartment of Internal Medicine, Medical Oncology, School of Medicine, Kyorin UniversityAbstract: Raf kinases and vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) tyrosine kinases are potential molecular targets for obtaining both anti-tumor cell progression and anti-angiogenesis effects in cancers, including hepatocellular carcinoma (HCC). Sorafenib is an oral multi-kinase inhibitor that mainly targets Raf kinases and receptor tyrosine kinases associated with angiogenesis (VEGFR-2/-3, PDGFR-β). A global randomized controlled trial (RCT) of sorafenib versus placebo conducted in patients with advanced HCC demonstrated the beneficial effects of the drug on the time-to-progression and overall survival. Furthermore, a RCT with a similar design to that of the global trial conducted in the Asia-Pacific region also demonstrated the efficacy of the drug. The most common treatment-related adverse events of sorafenib were found to be diarrhea, fatigue, and skin toxicity, namely, hand-foot syndromes and rash. Based on the results of the RCTs, sorafenib has been established as a standard agent for systemic chemotherapy in HCC patients with metastatic disease or transcatheter arterial chemoembolization (TACE)-refractory disease who are not suitable candidates for local treatments. The efficacy and safety of sorafenib in patients with moderate liver dysfunction have not been confirmed to date and more data are needed. Development of new therapeutic methods is needed for the treatment of advanced HCC in the future; clinical trials of sorafenib-based combination therapy, second-line therapy after sorafenib failure, and adjuvant therapy after local treatments are warranted in HCC patients.Keywords: hepatocellular carcinoma, sorafenib, raf kinase, vascular endothelial growth factor receptor, platelet-derived growth factor receptor
Page 1 /388
Display every page Item


Home
Copyright © 2008-2017 Open Access Library. All rights reserved.